Exparel is Pacira’s flagship pain-management product, which was launched in 2012. The drug is indicated for postsurgical local analgesia in patients aged six years and older.

The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx ...

Pacira BioSciences’ PCRX shares plunged 47.7% on Aug 9, after the U.S. District Court for the District of New Jersey ruled ...